The first HIV vaccine dose has gone on trial in the USA, giving great hope to scientists in finding an effective HIV vaccine.
After the first dose, which is still in the trial stages, was recently administered at George Washington University School of Medicine and Health Sciences in the United States, the world may be one step closer to developing an HIV vaccine.
If the HIV vaccine proves to be effective, it has the potential to revolutionize the world having stayed HIV for decades without cure.
According to the World Health Organization, around two million new HIV infections are recorded each year worldwide (WHO).
The International Aids Vaccine Initiative (IAVI), a nonprofit scientific research organization, and biotechnology business Moderna are leading development on the vaccine, mRNA-1644.
So far, 56 HIV-negative people ranging in age from 18 to 50 have signed up.
The vaccination will be administered to 48 volunteers, 32 will receive a booster shot, and the remaining eight will receive a booster shot.
Moderna will then keep an eye on the entire group for the next six months to ensure their safety.
The HIV vaccine mRNA-1644 is being developed using the same technology as the Covid-19 vaccines.
The hunt for an HIV vaccine has been long and difficult, according to Mark Feinberg, President, and CEO of IAVI, but “having new tools and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine.”
The Bill and Melinda Gates Foundation, Moderna, and the US National Institute of Allergy and Infectious Diseases are among those sponsoring the HIV vaccine.